European medical approval for Lyrica refused

The drugs company Pfizer have been refused marketing approval for Lyrica (also known as Pregablin) as a treatment for Fibromyalgia within the Europe Union. The Committee for Medicinal Products for Human Use (CHMP) will publish the reason for its decision to give a negative opinon in this case at a later date.

This decision follows the refusal to grant a marketing approval for Cymbalta as a treatment for Fibromyalgia in October 2008. There are no treatments for Fibromyalgia which have European Marketing Approval at present. We have no doubt that this decision represents a significant setback for people suffering from fibromyalgia in Europe and will only increase the frustrations of sufferers as they continue to fight for recognition and proper treatment of their condition.

< Prev		Next >

Written by Des Quinn (A)

Last Updated on Monday, 27 April 2009 11:47 Created: Thursday, 23 April 2009 20:23